The peritoneal cancer index as a predictor of complete cytoreduction at primary and interval cytoreductive surgery in advanced ovarian cancer.


Journal

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
ISSN: 1525-1438
Titre abrégé: Int J Gynecol Cancer
Pays: England
ID NLM: 9111626

Informations de publication

Date de publication:
06 11 2023
Historique:
medline: 8 11 2023
pubmed: 28 10 2023
entrez: 27 10 2023
Statut: epublish

Résumé

The peritoneal cancer index quantitatively assesses cancer distribution and tumor burden in the peritoneal cavity. The aim of this study is to evaluate the association between the peritoneal cancer index and completeness of surgical cytoreduction for ovarian cancer and to identify a cut-off above which complete cytoreduction is unlikely. This is a single-center prospective cohort observational study. A total of 100 consecutive patients who underwent ovarian cancer surgery were included. Peritoneal cancer index scores prior to and after surgery were calculated, and a cut-off value for incomplete cytoreduction was identified using a receiver operator characteristic (ROC) curve. Surgical complexity, blood loss, length of surgery, and complications were analyzed and associations with the peritoneal cancer index score were evaluated. The overall median peritoneal cancer index score was 9.5 (range 0-36). The median age of the patients was 61 years (range 24-85). The most common stage was III (13% stage II, 53% stage III, 34% stage IV) and the most common histologic sub-type was high-grade serous (76% high-grade serous, 8% low-grade serous, 5% clear cell, 4% serous borderline, 2% endometrioid, 2% adult granulosa cell, 2% adenocarcinoma, 1% carcinosarcoma). Complete cytoreduction was achieved in 82% of patients, with a median score of 9 (range 0-30). The remaining 18% had a median score of 28.5 (range 0-36). The best predictor of incomplete cytoreduction was the peritoneal cancer index score, with an area under the curve (AUC) of 0.928 (95% CI 0.85 to 1.00). ROC curve analysis determined a peritoneal cancer index cut-off score of 20. Major complications occurred in 15% of patients with peritoneal cancer index scores >20 and in 2.5% of patients with scores ≤20, which was statistically significant (p=0.014). In our study we found that a peritoneal cancer index score of ≤20 was associated with a high likelihood of complete cytoreduction. Incorporating the peritoneal cancer index into routine surgical practice and research may impact treatment plans.

Identifiants

pubmed: 37890875
pii: ijgc-2022-004093
doi: 10.1136/ijgc-2022-004093
doi:

Types de publication

Observational Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1757-1763

Informations de copyright

© IGCS and ESGO 2023. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Paula J Fagan (PJ)

Department of Gynaecological Oncology, The Royal Marsden NHS Foundation Trust, London, UK paulafagan@gmail.com.
Gynaecological Cancer Unit, St George's University Hospitals NHS Foundation Trust, London, UK.

Nana Gomes (N)

Department of Gynaecological Oncology, The Royal Marsden NHS Foundation Trust, London, UK.
The Institute of Cancer Research (ICR), London, UK.

Owen M Heath (OM)

Department of Gynaecological Oncology, The Royal Marsden NHS Foundation Trust, London, UK.

Dhivya Chandrasekaran (D)

Department of Gynaecological Oncology, The Royal Marsden NHS Foundation Trust, London, UK.
Department of Gynaecological Oncology, University College London Hospitals NHS Foundation Trust, London, UK.

Shih-Ern Yao (SE)

Department of Gynaecological Oncology, Monash Cancer Centre, Bentleigh East, Victoria, Australia.

Laura Satchwell (L)

Department of Gynaecological Oncology, The Royal Marsden NHS Foundation Trust, London, UK.

Angela George (A)

Department of Gynaecological Oncology, The Royal Marsden NHS Foundation Trust, London, UK.
The Institute of Cancer Research (ICR), London, UK.

Susana Banerjee (S)

Department of Gynaecological Oncology, The Royal Marsden NHS Foundation Trust, London, UK.
The Institute of Cancer Research (ICR), London, UK.

Aslam Sohaib (A)

Department of Gynaecological Oncology, The Royal Marsden NHS Foundation Trust, London, UK.

Desmond P Barton (DP)

Department of Gynaecological Oncology, The Royal Marsden NHS Foundation Trust, London, UK.
Gynaecological Cancer Unit, St George's University Hospitals NHS Foundation Trust, London, UK.

Marielle Nobbenhuis (M)

Department of Gynaecological Oncology, The Royal Marsden NHS Foundation Trust, London, UK.

Thomas Ind (T)

Department of Gynaecological Oncology, The Royal Marsden NHS Foundation Trust, London, UK.
St George's University of London, London, UK.

John Butler (J)

Department of Gynaecological Oncology, The Royal Marsden NHS Foundation Trust, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH